Gradient Investments LLC Trims Stake in Pfizer Inc. $PFE

Gradient Investments LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 22.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 123,804 shares of the biopharmaceutical company’s stock after selling 36,504 shares during the period. Gradient Investments LLC’s holdings in Pfizer were worth $3,083,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Armstrong Advisory Group Inc. raised its position in shares of Pfizer by 46.5% in the 4th quarter. Armstrong Advisory Group Inc. now owns 10,484 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 3,328 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Pfizer by 3.2% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,414,548 shares of the biopharmaceutical company’s stock worth $86,841,000 after buying an additional 105,368 shares during the last quarter. Gryphon Financial Partners LLC lifted its stake in shares of Pfizer by 13.6% during the fourth quarter. Gryphon Financial Partners LLC now owns 9,305 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 1,117 shares during the period. Wedmont Private Capital increased its position in shares of Pfizer by 18.7% in the 4th quarter. Wedmont Private Capital now owns 36,991 shares of the biopharmaceutical company’s stock valued at $935,000 after acquiring an additional 5,825 shares during the period. Finally, Value Partners Investments Inc. grew its stake in Pfizer by 0.4% during the 4th quarter. Value Partners Investments Inc. now owns 164,624 shares of the biopharmaceutical company’s stock valued at $4,100,000 after purchasing an additional 624 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Monday, March 2nd. Bank of America reduced their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Citigroup began coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective on the stock. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.14.

Pfizer Trading Down 0.7%

Shares of PFE stock opened at $26.77 on Tuesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The firm has a market capitalization of $152.23 billion, a P/E ratio of 19.68 and a beta of 0.47. The stock’s fifty day moving average is $26.71 and its two-hundred day moving average is $25.63. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.63 earnings per share. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 topline shows robust efficacy (~73% in pre-specified analyses), signaling clear commercial potential if regulators accept the data and approve the shot. BusinessWire: Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
• Positive Sentiment: Pfizer’s defensive income profile (high dividend yield cited in market coverage) and recent YTD recovery are attracting dividend‑focused investors, providing demand support amid market volatility. MarketBeat: 5 High-Yield Stocks to Shield Your Portfolio From the Storm
• Positive Sentiment: Technical/market narrative: coverage notes Pfizer is showing signs of outperformance versus prior years, which can attract momentum and rotation flows into the name. Fool: Pfizer Stock Is Doing Something It Hasn’t Done Since 2022
• Neutral Sentiment: Pfizer says it will pursue regulatory submissions despite the trial missing its formal primary endpoint — this keeps an approval path alive but raises review uncertainty and timing questions. CNBC: Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
• Negative Sentiment: The trial failed to meet its primary endpoint due to a low number of infection events, making the results statistically inconclusive and injecting regulatory and commercial risk; partner Valneva’s stock plunged on the news, reflecting investor concern about approval odds and program economics. WSJ: Pfizer’s Lyme Vaccine Shows Strong Efficacy but Misses Mark in Study

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.